Document:

Form of Amendment to Employment Agreement

 Exhibit 10.59 
 AMENDMENT TO EMPLOYMENT AGREEMENT 
 This AMENDMENT TO EMPLOYMENT AGREEMENT (the
“Amendment”) is made and entered into on July     , 2007, by and between JAZZ PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and
                                        
(the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”. 
 RECITALS 
 A. The Company retained the
services of the Executive pursuant to an employment agreement, dated February 14, 2004 (the “Previous Employment Agreement”). 
 B. The Parties wish to amend the Previous Employment Agreement to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. 
 AGREEMENT 
 1. Sections 7 through 25
of the Previous Agreement are hereby renumbered as Sections 8 through 26, respectively, and all Section references in the Previous Agreement shall be updated accordingly. 
 2. New Section 7 is hereby inserted to read as follows: 
 7. Application of Internal Revenue Code
Section 409A. 
 Since each arrangement providing for cash payments (except reimbursement of COBRA premiums)
pursuant to Sections 6.3, 6.4, and 6.5 (the “Payments”) constitutes a “nonqualified deferred compensation plan” within the meaning of Section 409A(d) of the Internal Revenue Code of 1986, as amended (the
“Code”), if the Executive is a “specified employee” of the Company (or any successor entity thereto) within the meaning of Section 409A(a)(2)(B)(i) of the Code on the applicable date, then solely to the extent
necessary to avoid the adverse personal tax consequences under Section 409A(a)(1) of the Code, the timing of the Payments shall be delayed to occur on the earlier of: (i) the date that is six months after the date of Executive’s
separation from service, or (ii) the date of Executive’s death (such date, the “Delayed Initial Payment Date”), and the Company (or the successor entity thereto, as applicable) shall (A) pay to the Executive a
lump sum amount equal to the sum of the Payments that Executive would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the Payments had not been delayed pursuant to this Section 7, and
(B) commence paying the balance of the Payments in accordance with the applicable payment schedules set forth herein. 
  

 1. 

 IN WITNESS WHEREOF, the Parties have executed this Amendment on July __, 2007, to be effective
immediately. 
  

			
	JAZZ PHARMACEUTICALS, INC.
		
	By:	 	  

	Its:	 	  

	
	EXECUTIVE:
	
	  

	[TYPE NAME]
		
	Address:	 	  

		 	  

  

 2.Form of Letter

 Exhibit 10.60 
 

 
 August 10, 2007 
  

	Re:	Outstanding Options to Purchase Shares of Jazz Pharmaceuticals, Inc. 

 Dear Option Holder: 
 You currently hold stock options (collectively, the “Options”) to purchase shares of common stock of
Jazz Pharmaceuticals, Inc. (the “Company”) under the Company’s 2003 Equity Incentive Plan (the “2003 Plan”). 
 Presently, each of your Options is structured so that the vesting and exercisability of your Options will accelerate with respect to an additional 25% of the option shares (or such lesser amount of shares as are then unvested and subject to
the option) if: (a) a change in control occurs, and (b) your employment is terminated without cause within 12 months thereafter. The terms of such acceleration are documented in an option agreement between you and the Company under the
2003 Plan. 
 We are pleased to announce that the Company’s Compensation Committee has approved an amendment to each of your Options which will provide,
in addition to the rights above, that in the event that your “continuous service” terminates due to an “involuntary termination without cause,” within either 12 months following, or one month prior to, the effective date of a
“change in control,” the vesting and exercisability of your Options will accelerate in full. 
 For purposes of such vesting acceleration,
“continuous service” and “change in control” shall have the meaning set forth in the Company’s 2007 Equity Incentive Plan (the “2007 Plan”). To review the definitions described in this paragraph,
please refer to the 2007 Plan, which you can read on livelink under Resources/Employees/Employee Stock Plans/2007 Equity Incentive Plan. 
 In addition,
“involuntary termination without cause” shall mean the involuntary termination of your “continuous service” (as defined in the 2007 Plan) for reasons other than death, “disability” (as defined in the 2007 Plan), or
“cause.” For this purpose, “cause” means that, in the reasonable determination of the Company, you have (i) committed an intentional act or acted with gross negligence that has materially injured the business of the Company;
(ii) intentionally refused or failed to follow lawful and reasonable directions of the Board or the appropriate individual to whom you report; (iii) willfully and habitually neglected your duties for the Company; or (iv) been
convicted of a felony involving moral turpitude that is likely to inflict or has inflicted material injury on the business of the Company. Notwithstanding the foregoing, “cause” shall not exist based on conduct described in clause
(ii) or (iii) unless the conduct described in such clause has not been cured within fifteen (15) days following your receipt of written notice from the Company specifying the particulars of the conduct constituting “cause.”
Any determination by the Company that your Continuous Service (as defined in the 2007 Plan) was terminated by reason of dismissal without “cause” for purposes of your Options shall have no effect upon any determination of the rights or
obligations of you or the Company for any other purpose. 
 

 

 

 
 We hope that you find this amendment to be a valuable addition to each of your outstanding Options. Except for the foregoing,
all remaining terms and conditions applicable to your Options will continue in full force and effect. Until your fully executed Acknowledgment (attached to this Notice) is received by the Company, your Options will not have the additional
acceleration provisions specified in this Notice. Please maintain a copy of this Notice with the other paperwork for your Options so that you will have a permanent record of this new amendment. If you have any questions concerning your amended
option, please contact Linda Weber, our Stock Plan Administrator and if you have questions about this amendment, please contact Scott Meggs, our Sr. Corporate Counsel. 
  

	
	 Very truly yours,

	
	 Jazz Pharmaceuticals, Inc.

 ACKNOWLEDGMENT 
 The undersigned acknowledges receipt of the foregoing Notice and agrees with the terms and conditions specified therein. Specifically, the undersigned
agrees to the application of the definitions regarding the amendment to the Options, and acknowledges that he or she has been provided with the opportunity to review a copy of the Company’s 2007 Equity Incentive Plan that contains the
additional definitions applicable to the Options. 
  

					
	 Dated:
                                , 2007
	 		  	
		 		  	  

		 		  	Signature
			
		 		  	  

		 		  	Print NameNon-Employee Director Compensation Arrangements

 Exhibit 10.61 
 JAZZ PHARMACEUTICALS, INC. 
 NON-EMPLOYEE DIRECTOR 
 COMPENSATION ARRANGEMENTS 
 (as
modified on July 18, 2007) 
 On May 1, 2007, the Board of Directors (the “Board”) of Jazz
Pharmaceuticals, Inc. (the “Company”) adopted the following compensation program for non-employee directors of the Board to be effective upon the closing of the initial public offering of the Company’s common stock (the
“Offering”). Pursuant to this program, each member of the Board who is not an employee or an officer of the Company will receive the following cash compensation for Board services (“Board Retainers”),
as applicable: 
  

	 	•	 	 a $30,000 annual retainer for service as a Board member; 

  

	 	•	 	 a $15,000 supplemental annual retainer for service as chair of the audit committee; 

  

	 	•	 	 a $10,000 supplemental annual retainer for service as chair of the compensation committee; and 

  

	 	•	 	 a $5,000 supplemental annual retainer for service as chair of each other committee of the Board. 

 The Company will continue to reimburse its non-employee directors for their reasonable expenses incurred in attending meetings of the Board and
committees of the Board. 
 Additionally, members of the Board who are not employees or officers of the Company will receive non-statutory
stock options under the Company’s 2007 Non-Employee Directors Stock Option Plan which will become effective immediately upon the signing of the underwriting agreement for the Offering. Each non-employee director joining the Board after the
closing of the Offering will automatically be granted a non-statutory stock option to purchase 30,000 shares of common stock with an exercise price equal to the then fair market value of the Company’s common stock. On the first trading day on
or after August 15 of each year, commencing on August 15, 2007, each non-employee director will automatically be granted a non-statutory stock option to purchase 10,000 shares of common stock on that date with an exercise price equal to
the then fair market value of the Company’s common stock. The initial grants will vest with respect to one-third of the shares on the first anniversary of the date of grant, and the balance in a series of 24 successive equal monthly
installments thereafter. The annual grants will vest in a series of 12 successive equal monthly installments measured from the date of grant. All stock options granted under the Company’s 2007 Non-Employee Directors Stock Option Plan will have
a maximum term of ten years. 
 On July 18, 2007, the Board determined that the Board Retainers for the periods from
(i) June 1, 2007 through August 14, 2007 (in an amount equal to 20.83% of the annual Board Retainer) and (ii) August 15, 2007 through August 14, 2008 shall be deemed earned and payable on August 15, 2007 and that
commencing August 15, 2008, Board Retainers for each annual period from August 15 to the next subsequent August 14 shall be deemed earned and payable in advance on August 15. Payments of Board Retainers are subject to a
non-employee’s director’s election pursuant to the Company’s Directors Deferred Compensation Plan.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]